Paul Chamberlain, Advisory Board member and NDA Group Biopharmaceuticals Expert, has been invited to give a presentation titled “Challenges in assessing relative immunogenicity (biosimilar and manufacturing change)” at an EMA Immunogenicity Workshop held in London on 9th March.
This EMA Workshop is intended to complement the external consultation with a discussion among experts on the key issues relevant to the assays and methods used to explore and assess the immunogenicity of therapeutic proteins.
For more information about the workshop click here.
